All lobbying filings

AVENUE SOLUTIONS

Lobbying for BRISTOL-MYERS SQUIBB COMPANY · Biopharmaceutical Company

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to prescription drugs, including 340B program

Medicare/Medicaid

Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA); Issues related to Most Favored Nation (MFN)

Bills named in this filing 2

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
S. 3019
No Big Blockbuster Bailouts Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.